Nursing practice questions with comprehensive rationales
NurseDive Free Nursing Practice Question
A patient is taking levetiracetam (Keppra) to treat seizures. Routine education for levetiracetam includes reminding them:
A. To report weight loss if it occurs
Weight loss is not a characteristic or clinically significant adverse effect that requires routine monitoring in patients taking Levetiracetam (Keppra). In some cases, patients may experience decreased appetite or weight changes, but this is not a primary safety concern. Routine counseling focuses more on neuropsychiatric effects such as irritability, mood changes, or depression rather than weight monitoring.
B. To wear sunscreen due to photosensitivity from levetiracetam
Photosensitivity is not a known adverse effect of Levetiracetam (Keppra). Unlike some medications such as tetracyclines or certain diuretics, levetiracetam does not significantly increase sensitivity to sunlight. Therefore, routine sunscreen use is not specifically required as part of standard medication counseling for this drug.
C. To get an annual eye exam while on levetiracetam
An annual eye exam is not a standard monitoring requirement for patients on Levetiracetam (Keppra). Some anticonvulsants, like vigabatrin, require ophthalmologic monitoring due to risk of visual field defects, but levetiracetam does not have known ocular toxicity that necessitates routine eye screening.
D. To not abruptly discontinue levetiracetam due to risk for withdrawal seizures
Abrupt discontinuation of Levetiracetam (Keppra) can lead to withdrawal seizures or increased seizure frequency due to sudden loss of neuronal stabilization. Patients should be instructed to taper the medication gradually under medical supervision rather than stopping it suddenly. This is a key safety teaching point for all anticonvulsant therapies to prevent rebound seizure activity.
This question is an excerpt from Nurse Dive's nursing test bank - Pharmacology proctored exam. Take the full exam now
Full Explanation
Levetiracetam (Keppra) is a broad-spectrum anticonvulsant used in the management of partial-onset seizures, myoclonic seizures, and generalized tonic-clonic seizures. It works by modulating neurotransmitter release through binding to synaptic vesicle protein SV2A, helping stabilize neuronal activity. Patient education is essential to ensure adherence and prevent breakthrough seizures. One of the most important safety concerns with anticonvulsants is avoiding sudden discontinuation.
Rationale:
A. Weight loss is not a characteristic or clinically significant adverse effect that requires routine monitoring in patients taking Levetiracetam (Keppra). In some cases, patients may experience decreased appetite or weight changes, but this is not a primary safety concern. Routine counseling focuses more on neuropsychiatric effects such as irritability, mood changes, or depression rather than weight monitoring.
B. Photosensitivity is not a known adverse effect of Levetiracetam (Keppra). Unlike some medications such as tetracyclines or certain diuretics, levetiracetam does not significantly increase sensitivity to sunlight. Therefore, routine sunscreen use is not specifically required as part of standard medication counseling for this drug.
C. An annual eye exam is not a standard monitoring requirement for patients on Levetiracetam (Keppra). Some anticonvulsants, like vigabatrin, require ophthalmologic monitoring due to risk of visual field defects, but levetiracetam does not have known ocular toxicity that necessitates routine eye screening.
D. Abrupt discontinuation of Levetiracetam (Keppra) can lead to withdrawal seizures or increased seizure frequency due to sudden loss of neuronal stabilization. Patients should be instructed to taper the medication gradually under medical supervision rather than stopping it suddenly. This is a key safety teaching point for all anticonvulsant therapies to prevent rebound seizure activity.
Similar Questions
A young adult female has severe cystic acne and is requesting treatment with Accutane (isotretinoin) after failing many therapies under your care. The appropriate response is to:
A. Prescribe isotretinoin (Accutane) after obtaining a thyroid stimulating hormone level
Obtaining a thyroid stimulating hormone (TSH) level is not a prerequisite for initiating Isotretinoin (Accutane) therapy. While baseline labs such as liver function tests and lipid profiles are commonly required, thyroid function testing is not routinely indicated. Additionally, isotretinoin initiation requires structured monitoring and prescribing under appropriate protocols, typically managed by dermatology.
B. Refer her to a dermatologist for evaluation and potential treatment
Referral to a dermatologist is the most appropriate action because Isotretinoin (Accutane) requires specialized oversight due to its high-risk profile, including severe teratogenicity and potential psychiatric and metabolic side effects. Dermatologists are trained to manage enrollment in risk management programs, monitor laboratory values, and ensure safe use, especially in reproductive-age females.
C. Discuss that isotretinoin (Accutane) is contraindicated in females and prescribe an oral tetracycline
Stating that isotretinoin is contraindicated in all females is incorrect because it is not absolutely contraindicated; rather, it is strictly controlled in females of reproductive potential. With proper enrollment in pregnancy prevention programs and adherence to contraception requirements, it can be safely prescribed. Oral tetracyclines are not appropriate substitutes for severe cystic acne and are also contraindicated in pregnancy.
D. Educate that her response is typical and it does not require treatment escalation
Severe cystic acne does require treatment escalation when first-line therapies fail, as untreated disease can result in permanent scarring and significant psychological impact. Minimizing the condition as “typical” ignores the progressive and potentially disfiguring nature of severe acne. Escalation to advanced therapies such as Isotretinoin (Accutane) is standard of care when indicated.
Full Explanation
Severe cystic acne is a deep, inflammatory form of acne vulgaris that can lead to scarring and significant psychosocial distress if not properly managed. Isotretinoin (Accutane) is one of the most effective treatments for refractory severe acne but requires strict monitoring due to its teratogenicity and potential systemic side effects. Initiation of this medication involves specialized prescribing programs and careful risk evaluation. Referral to a specialist ensures safe and appropriate management.
Rationale:
A. Obtaining a thyroid stimulating hormone (TSH) level is not a prerequisite for initiating Isotretinoin (Accutane) therapy. While baseline labs such as liver function tests and lipid profiles are commonly required, thyroid function testing is not routinely indicated. Additionally, isotretinoin initiation requires structured monitoring and prescribing under appropriate protocols, typically managed by dermatology.
B. Referral to a dermatologist is the most appropriate action because Isotretinoin (Accutane) requires specialized oversight due to its high-risk profile, including severe teratogenicity and potential psychiatric and metabolic side effects. Dermatologists are trained to manage enrollment in risk management programs, monitor laboratory values, and ensure safe use, especially in reproductive-age females.
C. Stating that isotretinoin is contraindicated in all females is incorrect because it is not absolutely contraindicated; rather, it is strictly controlled in females of reproductive potential. With proper enrollment in pregnancy prevention programs and adherence to contraception requirements, it can be safely prescribed. Oral tetracyclines are not appropriate substitutes for severe cystic acne and are also contraindicated in pregnancy.
D. Severe cystic acne does require treatment escalation when first-line therapies fail, as untreated disease can result in permanent scarring and significant psychological impact. Minimizing the condition as “typical” ignores the progressive and potentially disfiguring nature of severe acne. Escalation to advanced therapies such as Isotretinoin (Accutane) is standard of care when indicated.
A patient is started on sertraline (Zoloft), an SSRI, for depression. Education regarding this class of medications includes:
A. Red-green color blindness may occur
Red-green color blindness is not associated with Sertraline (Zoloft). SSRIs do not affect retinal cone function or visual color processing pathways. Visual disturbances are not a recognized class effect, and this reflects a misconception unrelated to SSRI pharmacology or safety profile.
B. SSRIs may take up to 4-8 weeks before maximum effect.
SSRIs such as Sertraline (Zoloft) typically require 4–8 weeks to achieve maximum therapeutic effect because neurochemical and receptor adaptations in the brain take time. While some early improvement in sleep or anxiety may occur, full antidepressant effects are delayed. Educating patients about this timeline helps prevent premature discontinuation due to perceived lack of benefit.
C. Chest pain is common and can be alleviated by taking aspirin as needed
Chest pain is not a common or expected adverse effect of Sertraline (Zoloft) and should not be managed with aspirin as a routine response. Chest pain should always be evaluated for potential cardiac or other serious causes rather than attributed to SSRI therapy.
D. Probiotics may help to prevent diarrhea
Probiotics are not part of standard education for preventing diarrhea related to Sertraline (Zoloft). While mild gastrointestinal upset such as nausea or diarrhea may occur initially with SSRIs, these symptoms usually resolve over time without specific probiotic therapy. Management is typically supportive and focused on tolerance rather than routine supplementation.
Full Explanation
Selective serotonin reuptake inhibitors (SSRIs) such as Sertraline (Zoloft) are commonly used first-line treatments for major depressive disorder. These medications work by increasing serotonin availability in the central nervous system, improving mood and anxiety symptoms over time. Unlike acute symptom-relief medications, SSRIs require consistent daily use and a delayed onset of full therapeutic effect. Patient education is essential to set realistic expectations and improve adherence during the initial treatment period.
Rationale:
A. Red-green color blindness is not associated with Sertraline (Zoloft). SSRIs do not affect retinal cone function or visual color processing pathways. Visual disturbances are not a recognized class effect, and this reflects a misconception unrelated to SSRI pharmacology or safety profile.
B. SSRIs such as Sertraline (Zoloft) typically require 4–8 weeks to achieve maximum therapeutic effect because neurochemical and receptor adaptations in the brain take time. While some early improvement in sleep or anxiety may occur, full antidepressant effects are delayed. Educating patients about this timeline helps prevent premature discontinuation due to perceived lack of benefit.
C. Chest pain is not a common or expected adverse effect of Sertraline (Zoloft) and should not be managed with aspirin as a routine response. Chest pain should always be evaluated for potential cardiac or other serious causes rather than attributed to SSRI therapy.
D. Probiotics are not part of standard education for preventing diarrhea related to Sertraline (Zoloft). While mild gastrointestinal upset such as nausea or diarrhea may occur initially with SSRIs, these symptoms usually resolve over time without specific probiotic therapy. Management is typically supportive and focused on tolerance rather than routine supplementation.
A 66-year-old male was prescribed phenelzine (Nardil) while in an acute psychiatric unit for recalcitrant depression. The nurse practitioner (NP) managing his primary health care needs to understand the following regarding phenelzine and other monoamine oxidase inhibitors (MAOIs):
A. He should not be prescribed any other serotonergic drugs to limit serotonin syndrome risk
Patients taking Phenelzine (Nardil) must avoid other serotonergic medications such as SSRIs, SNRIs, tramadol, and certain migraine medications due to the risk of serotonin syndrome. Excess serotonin accumulation can lead to agitation, hyperthermia, autonomic instability, and potentially life-threatening complications. A mandatory washout period is required when switching between serotonergic agents and MAOIs.
B. MAOIs interact with many common foods such as aged or fermented foods and require patient education
MAOIs require strict dietary restrictions because foods high in tyramine, such as aged cheeses, cured meats, fermented products, and certain alcoholic beverages, can trigger dangerous hypertensive crises. Phenelzine (Nardil) inhibits tyramine metabolism, leading to excessive norepinephrine release and severe vasoconstriction. Patient education about diet is a critical safety component of therapy.
C. MAOIs interact with many other drugs that will require careful consideration when prescribing future medications
MAOIs have extensive drug interactions with many commonly prescribed medications, including sympathomimetics, decongestants, certain analgesics, and other antidepressants. These interactions can result in hypertensive crisis or serotonin toxicity. Patients on Phenelzine (Nardil) require thorough medication reconciliation before any new prescriptions are given across all healthcare settings.
D. All options are correct.
All options are correct because MAOIs such as Phenelzine (Nardil) require avoidance of serotonergic drugs, strict dietary tyramine restriction, and careful evaluation of all potential drug interactions. These combined precautions are essential to prevent life-threatening complications and ensure safe long-term management of treatment-resistant depression.
Full Explanation
Phenelzine (Nardil) is a monoamine oxidase inhibitor (MAOI) used in treatment-resistant depression. MAOIs increase levels of serotonin, norepinephrine, and dopamine by inhibiting their breakdown, which significantly improves mood in refractory cases. However, this mechanism also creates a high risk for serious drug and food interactions, including hypertensive crisis and serotonin syndrome. Safe use requires strict dietary restrictions and careful medication review across all healthcare settings.
Rationale:
A. Patients taking Phenelzine (Nardil) must avoid other serotonergic medications such as SSRIs, SNRIs, tramadol, and certain migraine medications due to the risk of serotonin syndrome. Excess serotonin accumulation can lead to agitation, hyperthermia, autonomic instability, and potentially life-threatening complications. A mandatory washout period is required when switching between serotonergic agents and MAOIs.
B. MAOIs require strict dietary restrictions because foods high in tyramine, such as aged cheeses, cured meats, fermented products, and certain alcoholic beverages, can trigger dangerous hypertensive crises. Phenelzine (Nardil) inhibits tyramine metabolism, leading to excessive norepinephrine release and severe vasoconstriction. Patient education about diet is a critical safety component of therapy.
C. MAOIs have extensive drug interactions with many commonly prescribed medications, including sympathomimetics, decongestants, certain analgesics, and other antidepressants. These interactions can result in hypertensive crisis or serotonin toxicity. Patients on Phenelzine (Nardil) require thorough medication reconciliation before any new prescriptions are given across all healthcare settings.
D. All options are correct because MAOIs such as Phenelzine (Nardil) require avoidance of serotonergic drugs, strict dietary tyramine restriction, and careful evaluation of all potential drug interactions. These combined precautions are essential to prevent life-threatening complications and ensure safe long-term management of treatment-resistant depression.